Canadian Journal of Gastroenterology and Hepatology (Jan 2025)

Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data

  • David C. Sealey,
  • Kai Fai Ho,
  • Z. Christina Zhou,
  • Michael Clark,
  • Brian G. Feagan,
  • Remo Panaccione,
  • A. Hillary Steinhart,
  • Elena Bolshtyansky,
  • Martin Williamson,
  • Waqqas Afif

DOI
https://doi.org/10.1155/cjgh/5713315
Journal volume & issue
Vol. 2025

Abstract

Read online

Conclusion: TDM-associated dose optimization in patients with UC with low serum infliximab concentrations was associated with longer persistence. This association was not confirmed in patients with CD. This study demonstrated that real-world data from a PSP-generated cohort can be evaluated to inform clinical practice and that this approach may be complementary to other types of cohort studies.